Intradermal drug delivery: the field of dermatological research by sonophoresis M. Nino, G. Calabrò, A. Patalano and P. Santoianni Dept. of Systematic.

Slides:

Advertisements

Similar presentations

The ultimate Technology for Cellulites and Slimming.

Advertisements

Principles of Topical Treatments in Dermatology Doç. Dr.Burhan Engin.

Pimecrolimus 1% cream in the treatment of facial psoriasis: A 16-week open label study Jacobi A et al. One of authors Braeutigam M belongs to clinical.

Acne Treatment and Therapeutic Strategies

In Vivo Evaluation of a Mechanically-Oscillating Dual- Mode Applicator for Ultrasound Imaging and Thermal Ablation Neil Owen et al. IEEE Transactions on.

ALOPECIA ABDULMAJEED ALAJLAN, MD ASSISTANT PROFESSOR DERMATOLOGY DEPT.

Pharmacology-4 PHL 425 Third Lecture By Abdelkader Ashour, Ph.D. Phone:

Pharmaceutics 2 & 3 صيدلانيات 2&3 Unit / second semester Transdermal drug delivery system.

Mesotherapy for facial skin rejuvenation: A clinical, histologic and electron- microscopic evaluation. Amin S. et al. Dermatol Surg 2006; 32:

Pulse Electroporation System Onyx Medical Inc.. Various TDD Technologies Various TDD Technologies  Electroporation - Using short electrical modulated.

Biopotential Electrodes II. Motion Artifact When the electrode moves with respect to the electrolyte, Motion artifact is minimal for non-polarizable electrodes.

Methods For Monitoring Transdermal Drug Delivery Analytical/Radio/Nuclear (ARN) Seminar Jivan Yewle Department of Chemistry University of Kentucky.

Defining the right clinical problems for nanotechnology Table 2 John S. Oghalai, MD.

Clinical Studies South Korea: Dr. Jongmin Park South Korea: Dr. Dong-Hye Suh Brazil: Dr. Maria Claudia Issa Brazil: Dr. Tania Meneghel Dubai: Dr. Maria.

Absorption enhancements

Ablative laser skin resurfacing Dr.Ali A. Maazil Plastic and reconstructive surgeon in Alssadar medical city In Al Najaf 2012.

CHPA Comments on Efficacy and Labeling Issues for OTC Drug Products Used in the Treatment of Tinea Pedis CHPA Antifungal Task Group 6 May 2004.

Joint Dermatologic and Ophthalmic Drugs & Drug Safety and Risk Management Advisory Committee February 26 & 27, 2004 RISK MANAGEMENT OPTIONS FOR PREGNANCY.

Twenty Questions Subject: Diagnosis & Treatment Twenty Questions

Compounding Ointment (Unguentum) Dr. Muslim Suardi, MSi., Apt.

Pharmaceutics 2 Unit 4 Transdermal drug delivery systems

ALOPECIA & VITILIGO GHADA BINSAIF, MD ASSISTANT PROFESSOR & CONSULTANT DERMATOLOGIST KSU & KKUH.

Dermatology slide Haitham Bader Ninaveha Medical college.

Marketed By : Cipla Courtesy: ClickOnCare.com. Introduction VC 15 Vitamin C Serum is used to treat: Photodamaged aging skin Melasma Hyperpigmentation.

黄褐斑 chloasma melasma. Definiton Melasma (also known as Chloasma faciei, or the mask of pregnancy when present in pregnant women) is a tan or dark skin.

J Clin Oncol 28: R2 소예리 / Prof. 이재진. INTRODUCTION EGFR is overexpressed in 70-80% of pts with advanced colorectal cancer EGFR dysregulation:

M. Ansari COMPOUNDING FOR DERMATOLOGY PATIENTS. A CNE  Acne vulgaris is characterized by comedones and otherlesions, including scars and occurs throughout.

What’s New in Alopecia Areata Research ? Jul CANAAF COME TOGETHER Toronto, ON Jeff Donovan MD Update on Alopecia Areata Research Jeff Donovan.

Professor Philippe HUMBERT Research and Studies Center on the Integument (CERT) Department of Dermatology, Clinical Investigation Center (CIC BT506) Besançon.

Dr. Qassim Al-chalabi M.B.Ch.B F.A.B.H.S (Dermatology & Venereology)

Successful treatment of corticosteroid-resistant ophiasis-type alopecia areata (AA) with platelet-rich plasma (PRP) Jeff Donovan, MD, PhD, FRCPC JAAD.

A SEMINAR PRESENTATION ON ADMINISTRATION OF DRUGS AND VACCINES: THE SUGGESTED OPTIONS FOR AN ANIMAL PRODUCER. BY AKINADE, ABIODUN J. (APH/07/9885)

. X Alopecia None Scaring (Reversible) Scaring (Irreversible)

Omer Ibrahim, Wilma F. Bergfeld, Melissa Piliang

TRANSDERMAL DRUG DELIVERY SYSTEMS

Clinical efficacy of diphenylcyclopropenone in alopecia areata: Retrospective data analysis of 50 patients Katherine Chiang, BSE, Natasha Atanaskova.

Systematic review and quality analysis of studies on the efficacy of topical diphenylcyclopropenone treatment for alopecia areata Yong Hyun Jang, MD,

Hydroxychloroquine is ineffective in treatment of alopecia totalis and extensive alopecia areata: A case series of 8 patients Christoffer V. Nissen,

Introduction; Scope of Pharmacology Routes of Drug Administration

Tofacitinib 2% ointment, a topical Janus kinase inhibitor, for the treatment of alopecia areata: A pilot study of 10 patients Lucy Y. Liu, BA, Brittany.

Negative Electric Potential Induces Alteration of Ion Gradient and Lamellar Body Secretion in the Epidermis, and Accelerates Skin Barrier Recovery After.

Elana Putterman, BS, Leslie Castelo-Soccio, MD, PhD

nAMD: New Drugs and Practice Patterns to Improve Patient Outcomes

Sonicated transdermal drug transport – paper by Joshi and Raje, 2002

Volume 3, Issue 6, Pages (November 2017)

Autoimmune Disease Induction in a Healthy Human Organ: A Humanized Mouse Model of Alopecia Areata Amos Gilhar, Aviad Keren, Avner Shemer, Roberto d'Ovidio,

Treating CD30-Expressing Cutaneous T-Cell Lymphoma

Successful treatment of corticosteroid-resistant ophiasis-type alopecia areata (AA) with platelet-rich plasma (PRP) Jeff Donovan, MD, PhD, FRCPC JAAD.

Introduction to Pharmacology

Sonicated transdermal drug transport – paper by Joshi and Raje, 2002

Volume 4, Issue 10, Pages (November 2018)

How to Manage ISRs That Occur With Injectable Agents in Psoriasis

Cosmetic Benefits of Astaxanthin on Human Subjects

Mechanisms of LtxA (Leukotoxin), a Potent New Anti-Inflammatory Agent for the Treatment of Alopecia Areata Scott C. Kachlany Journal of Investigative.

Low-Frequency Sonophoresis: Ultrastructural Basis for Stratum Corneum Permeability Assessed Using Quantum Dots Sumit Paliwal, Gopinathan K. Menon, Samir.

Alopecia Areata: Treatment of Today and Tomorrow

Safety and Efficacy of Bimatoprost Solution 0

Clinical Efficacy of Diphenylcyclopropenone in Alopecia Areata: Retrospective Data Analysis of 50 Patients Katherine S. Chiang, Natasha A. Mesinkovska,

Volume 1, Issue 6, Pages (November 2015)

Seasonal patterns in alopecia areata, totalis, and universalis

Volume 3, Issue 6, Pages (November 2017)

Tofacitinib therapy for children with severe alopecia areata

Efficacy of topical diphenylcyclopropenone maintenance treatment for patients with alopecia areata: A retrospective study Sung Jay Choe, MD, Solam Lee,

Brittany G. Craiglow, MD, Brett A. King, MD, PhD

DRUGS USED IN CURRENT PHYSICAL THERAPY PRACTICE By Pashmina khan.

Presentation transcript:

Intradermal drug delivery: the field of dermatological research by sonophoresis M. Nino, G. Calabrò, A. Patalano and P. Santoianni Dept. of Systematic Pathology - Section of Dermatology - University of Naples Federico II INTRODUCTION The skin is an important barrier to the penetration of exogenous substances and a potential route for the transport of functional active principles. Several methods have been studied to increase the penetration for a systemic or a loco-regional effect. Sonophoresis is the main physical technique that increases cutaneous penetration of substances. It is based on 20 to 25 KHz ultrasounds that can induce alterations of the horny barrier through micromechanical, thermal and cavitation effects. MATERIALS AND METHODS This study evaluated the efficacy of low frequency sonophoresis (LFS) at 25 KHz produced by a sonicator for treatment of alopecia areata, melasma and solar lentigo. 30 patients affected by alopecia areata were treated for a 3- month period by 36 applications (three times a week) of methylprednisolone 0.5% pet. or cyclosporine 0.1% solution followed by LFS. 48 women with melasma and 48 with solar lentigo were treated for a 5-week period by 10 applications (twice a week) with a depigmenting emulsion based on cogic, azelaico and ascorbic acid and LFS application.

RESULTS For alopecia areata the results were: a) with methylprednisolone, 57% partial and 29% total regrowth (Figg. 1-3); b) with cyclosporine, 33% partial and 34% total regrowth (Figg. 4-6). For melasma: 25% partial and 75% complete depigmentation (Figg. 7-8). For solar lentigo: 57% partial and 43% total regression (Figg. 9-10). CONCLUSIONS The study shows that LFS is a not aggressive technique, enhances penetration of topic agents obtaining effects at the level of the epidermis, dermis and appendages (intradermal delivery), giving good results in the treatment of some cosmetic skin disorders.

Figg. 4,5,6: Treatment by cyclosporine + LFS: results in a patient. Before treatment (a), after 1-month treatment (b), after 3-month treatment (c). bac Figg. 1,2,3: Treatment by methylprednisolone + LFS: results in a patient. Before treatment (a), after 2-month treatment (b), after 3-month treatment (c). Alopecia areata abc

Melasma Figg.7-8: Treatment by emulsion + LFS: results in a patient with melasma. Before treatment and after 5-week treatment. Solar lentigo Figg. 9-10: Treatment by emulsion + LFS: results in a patient with solar lentigo. Before treatment and after 5-week treatment.